Redeye provides an update following Litium’s acquisition of Geins, a small but strategically sound deal that brings both technical capabilities and a customer base of some 25 clients. The transaction adds ~11% to ARR and the 6% rights issue discount and broad insider participation reflect strong backing. We lift our estimates slightly across the board.
LÄS MER
